Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synta initiates treatment in cancer study
The open-label, dose-escalation study of elesclomol in up to 30 subjects with advanced metastatic or unresectable solid tumors is designed to identify the maximum tolerated dose of elesclomol
The open-label, dose-escalation study of elesclomol in up to 30 subjects with advanced metastatic or unresectable solid tumors is designed to identify the maximum tolerated dose of elesclomol
Prior to joining MedMira, Smith was a member of the Nova Scotia Legislature for 19 years, serving in various roles including Minister of Health. Born and raised in
The transaction is expected to generate cash proceeds of $275 million from the sale of property and equipment. From these proceeds, $30 million will be deferred and placed
The studies, funded by the National Institutes for Health’s CounterACT program, have been designed to test the efficacy of AEOL 10150 as a treatment for damage to the
This change follows the resignation of Richard Donnelly from his roles as an officer and director of AspenBio. Mr Donnelly has indicated that he plans to pursue other
Through this agreement, BioWisdom gains access to the data within Asterand’s proprietary Target Evaluator database. The database consists of quantitative human gene expression profiles that chart the expression
Curis, a drug development company, has announced that its collaborator Genentech and the National Cancer Institute’s division of cancer treatment and diagnosis are planning to enter into a
The license grants Fovea exclusive marketing rights for DX-88 in ophthalmic indications in the EU. Dyax retains marketing rights for these indications for all territories outside the EU.
These data suggest that GS 9350 has significant and selective pharmacoenhancing ability, no antiviral activity against HIV and differentiated biological properties in vitro compared to ritonavir, currently the
This includes $191 million of revenue from its recent acquisition of Applied Biosystems (AB), which closed on November 21, 2008. The closing date of the transaction resulted in